Rituximab-Biosimilars Insight, 2022
![](/report_cover/8047/rituximab-biosimilars-insight-2020_en.gif)
This report can be delivered to the clients within 96-120 hours
DelveInsight’s, “Rituximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Rituximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Rituximab: Overview
Rituximab is a type of antibody therapy that can be used alone or with chemotherapy. They work in different ways to find and attack the cells where cancer starts. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling. This drug is also used to treat certain types of blood vessel disease (such as granulomatosis with polyangiitis, microscopic polyangiitis) and can decrease the swelling of the blood vessels. Rituximab is also used to treat a certain skin condition (pemphigus vulgaris). It helps to reduce the number of skin lesions.
Rituximab Biosimilars: Drugs Chapters
This segment of the Rituximab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rituximab Biosimilars: Marketed Drugs
Further product details are provided in the report……..
Rituximab Biosimilars: Emerging Drugs
Further product details are provided in the report……..
Rituximab: Therapeutic Assessment
This segment of the report provides insights about the different Rituximab biosimilars segregated based on following parameters that define the scope of the report, such as:
Rituximab: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Rituximab biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rituximab biosimilar drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Rituximab– Biosimilar 2022,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Rituximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Rituximab: Overview
Rituximab is a type of antibody therapy that can be used alone or with chemotherapy. They work in different ways to find and attack the cells where cancer starts. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling. This drug is also used to treat certain types of blood vessel disease (such as granulomatosis with polyangiitis, microscopic polyangiitis) and can decrease the swelling of the blood vessels. Rituximab is also used to treat a certain skin condition (pemphigus vulgaris). It helps to reduce the number of skin lesions.
Rituximab Biosimilars: Drugs Chapters
This segment of the Rituximab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rituximab Biosimilars: Marketed Drugs
- Blitzima: Celltrion
- Rixathon: Sandoz
Further product details are provided in the report……..
Rituximab Biosimilars: Emerging Drugs
- IBI301: Innovent Biologics
- ABP 798: Allergan/Amgen
Further product details are provided in the report……..
Rituximab: Therapeutic Assessment
This segment of the report provides insights about the different Rituximab biosimilars segregated based on following parameters that define the scope of the report, such as:
- Major Players in Rituximab
- Phases
- Marketed stage products
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Molecule Type
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type
Rituximab: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Rituximab biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rituximab biosimilar drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rituximab R&D. The therapies under development are focused on novel approaches to treat/improve Rituximab.
- In January 2019, Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE (rituximab), a potential biosimilar to MabThera (rituximab).
- In December 2019, Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.
- In November 2019, Teva Pharmaceuticals and Celltrion Healthcare announced that TRUXIMA (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan1 (rituximab) now available in the United States with a full oncology label. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL):
- Rituximab Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rituximab Biosimilars?
- How many Rituximab biosimilars are developed by each company?
- How many emerging biosimilars are in mid-stage, and late-stage?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rituximab biosimilars therapeutics?
- What are the clinical studies going on for Rituximab biosimilars and their status?
- What are the key designations that have been granted to the emerging drugs?
- Innovent Biologics
- IQVIA (formely Quintiles Transnational Corp)
- Gedeon Richter
- BioIntegrator
- Allergan
- Amgen
- Biocad
- Celltrion
- BioXpress Therapeutics
- Dr. Reddy's Laboratories Limited
- Sandoz
- Shanghai Henlius Biotech
- iBio
- Inbiopro Solutions
- Merck & Co.
- Gedeon Richter
- Zydus Cadila
- Curaxys
- Outlook Therapeutics
- Apotex
- mAbxience
- Pfizer
- Nichi-Iko Pharmaceutical/Aprogen
- Sunshine Guojian Pharmaceutical
- Lonza
- Teva Pharmaceutical Industries
- Reliance Life Sciences
- PROBIOMED
- LG Chem
- GC Pharma
- Hetero Group
- HisunPharmaceuticals
- BioXpress Therapeutics
- International Biotech Center Generium
- IBI-301
- RGB 03
- RITUMAX
- ABP 798
- AcellBia/Usmal
- Blitzima/Truxima
- BX 2336
- DRL_RI
- GP2013
- HLX01
- iBio Rituximab
- IBPB 001RX
- MK-8808
- Ritemvia/Blitzima
- Riximyo
- RTXM83
- Ruxience
- AP 052
- Retuxira
- TL-011
- RituxiRel
- Kikuzubam
- LBRx
- DRL-rituximab
- MG1106
- GB-241
- Rilast
- HS 006
- BX 2336
- GNR-006
1. KEY INSIGHTS
2. RITUXIMAB BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. RITUXIMAB (REFERENCE PRODUCT: RITUXAN)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. RITUXAN BIOSIMILAR: EMERGING OPPORTUNITIES
8. RITUXIMAB: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. RITUXIMAB BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Pfizer
9.1.1.1. Ruxience: Pfizer
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Innovent Biologics
9.1.2.1. IBI-301: Innovent Biologics
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
9.1.3. Celltrion
9.1.3.1. Blitzima: Celltrion
9.1.3.1.1. Product Information
9.1.3.1.2. Research and Development
9.1.3.1.3. Other Development Activities
9.1.3.1.4. General Description Table
9.1.4. Merck & Co.
9.1.4.1. MK-8808: Merck & Co.
9.1.4.1.1. Product Information
9.1.4.1.2. Research and Development
9.1.4.1.3. Other Development Activities
9.1.4.1.4. General Description Table
9.1.5. Sandoz
9.1.5.1. Riximyo: Sandoz
9.1.5.1.1. Product Information
9.1.5.1.2. Research and Development
9.1.5.1.3. Other Development Activities
9.1.5.1.4. General Description Table
9.1.5.2. GP2013: Sandoz
9.1.5.2.1. Product Information
9.1.5.2.2. Research and Development
9.1.5.2.3. Other Development Activities
9.1.5.2.4. General Description Table
*More Companies and products would be added in the final report
10. RITUXIMAB BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. RITUXIMAB BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. RITUXIMAB BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. RITUXIMAB (REFERENCE PRODUCT: RITUXAN)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. RESEARCH AND DEVELOPMENT
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. RITUXAN BIOSIMILAR: EMERGING OPPORTUNITIES
8. RITUXIMAB: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. RITUXIMAB BIOSIMILARS PROFILES: BY COMPANY
9.1.1. Pfizer
9.1.1.1. Ruxience: Pfizer
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Innovent Biologics
9.1.2.1. IBI-301: Innovent Biologics
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
9.1.3. Celltrion
9.1.3.1. Blitzima: Celltrion
9.1.3.1.1. Product Information
9.1.3.1.2. Research and Development
9.1.3.1.3. Other Development Activities
9.1.3.1.4. General Description Table
9.1.4. Merck & Co.
9.1.4.1. MK-8808: Merck & Co.
9.1.4.1.1. Product Information
9.1.4.1.2. Research and Development
9.1.4.1.3. Other Development Activities
9.1.4.1.4. General Description Table
9.1.5. Sandoz
9.1.5.1. Riximyo: Sandoz
9.1.5.1.1. Product Information
9.1.5.1.2. Research and Development
9.1.5.1.3. Other Development Activities
9.1.5.1.4. General Description Table
9.1.5.2. GP2013: Sandoz
9.1.5.2.1. Product Information
9.1.5.2.2. Research and Development
9.1.5.2.3. Other Development Activities
9.1.5.2.4. General Description Table
*More Companies and products would be added in the final report
10. RITUXIMAB BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. RITUXIMAB BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT